A video from JAMA featuring Steve Nissen, one of the authors of the STRADIVARIUS trial.
This trial was designed to show that Rimonabant ( a drug used for weight loss in several countries but not US) could reduce plaque build up in the arteries which is a surrogate risk marker for developing heart attack and stroke.
This study used two methods to measure the amount of plaque in the arteries. The main method (called percent atheroma volume) to measure plaque thickness did not show any benefit. However, the second method (called normalized total atheroma volume) did show some benefit. The clinical benefit of this medication therefore will need to determined by additional studies before it gets FDA approval.
Reference: JAMA
Tags: Atherosclerosis, Heart Attack, JAMA, Weight loss
Dear Dr. Bansal,
My medical news website, Hot Medical News http://hotmedicalnews.com, features a variety of well-researched and entertaining medical articles, with some that are quirky and a little offbeat. I think your readers would find my material very interesting. If you agree, perhaps you might link to my site.
I have a new article on Jack Kevorkian, who is running for Congress. The article details his mental illness as assessed by a former Johns Hopkins Chairman of Psychiatry, Paul HcHugh. There is also valuable material on the issue of assisted suicide.
Thanks for your time and consideration.
Sincerely,
Brian Carty, MD, MSPH
[Reply]